cefotaxime sandoz cefotaxime 2g powder for injection vial
sandoz pty ltd - cefotaxime sodium, quantity: 2096.4 mg (equivalent: cefotaxime, qty 2000 mg) - injection, powder for - excipient ingredients: - indications: cefotaxime is indicated for the treatment of the following types of infection when caused by susceptible micro-organisms. infections of the respiratory tract (upper and lower); infections of the urinary tract; septicaemia (concomitant therapy with an aminoglycoside may be instituted prior to isolation of the causative organism); intra-abdominal infection; gonorrhoea (including gonorrhoea caused by beta-lactamase producing strains of n. gonorrhoea); ear, nose and throat infections; skin and skin structure infections; bone and joint infections; meningitis: cefotaxime should be combined with an appropriate alternative antibiotic (ampicillin, chloramphenicol or benzylpenicillin) for initial therapy in children (excluding neonates) pending the availability of culture and sensitivity results. in adults the empirical use of cefotaxime should be restricted to patients suspected of having meningitis caused by gram-negative enteric bacilli. cefotaxime may be used for the prevention of post-operative infec
dbl cefotaxime sodium cefotaxime sodium 2.096g powder for injection vial
pfizer australia pty ltd - cefotaxime sodium, quantity: 2.096 g - injection, powder for - excipient ingredients: - indications: cefotaxime is indicated for the treatment of the following types of infection when caused by susceptible micro-organisms: infections of the respiratory tract (upper and lower). infections of the urinary tract. septicaemia - concomitant therapy with an aminoglycoside may be instituted prior to isolation of the causative organism. intra-abdominal infection. gonorrhoea (including gonorrhoea caused by beta lactamase producing strains of n.gonorrhoeae). ear, nose and throat infections. skin and skin structure infections. bone and joint infections. meningitis - cefotaxime should be combined with an appropriate alternative antibiotic (ampicillin, chloramphenicol or penicillin g) for initial therapy in children, (excluding neonates) pending the availabiliy of culture and sensitivity results. in adults, the empirical use of cefotaxime should be restricted to patients suspected of having meningitis caused by gram negative enteric bacilli. cefotaxime may be used for the prevention of post-operative infe
cefotaxime sodium for injection 500mg powder for solution for injection or infusion
villerton invest s.a. rue edward steichen 14, 2540, luxembourg - cefotaxime sodium - powder for solution for injection/infusion - cefotaxime sodium 500/2.2 mci/ml - antibacterials for systemic use
cefotaxime sodium for injection 1g powder for solution for injection or infusion
villerton invest s.a. rue edward steichen 14, 2540, luxembourg - cefotaxime sodium - solution for injection/infusion - cefotaxime sodium 1/4.4 g/ml - antibacterials for systemic use
cefotaxime (aft)
aft pharmaceuticals ltd - cefotaxime sodium 1048.1mg equivalent 1 g cefotaxime (+ 5% overage) - powder for injection - 1 g - active: cefotaxime sodium 1048.1mg equivalent 1 g cefotaxime (+ 5% overage) - cefotaxime is indicated in the treatment of the following infections either before the infecting organism has been identified or when caused by bacteria of established sensitivity. · septicaemia. · respiratory tract infections: acute and chronic bronchitis, bacterial pneumonia, infected bronchiectasis, lung abscess and post-operative chest infections. · urinary tract infections: acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. · soft tissue infections: cellulitis, peritonitis and wound infections. · bone and joint infections: osteomyelitis, septic arthritis. · obstetric and gynaecological infections: pelvic inflammatory disease. · gonorrhoea: particularly if penicillin-resistant. · other bacterial infections: meningitis and other sensitive infections suitable for parenteral antibiotic therapy. the administration of cefotaxime prophylactically may reduce the incidence of certain post-operative infections in patients undergoing surgical procedures that are classified as contaminated or potentially contaminated or in clean operations where infections would have serious effects. protection is best ensured by achieving adequate local tissue concentrations at the time contamination is likely to occur. cefotaxime should therefore be administered immediately prior to surgery and if necessary continued in the immediate post-operative period. administration should usually be stopped within 24 hours since continuing use of any antibiotic in the majority of surgical procedures does not reduce the incidence of subsequent infections.
cefotaxime (aft)
aft pharmaceuticals ltd - cefotaxime sodium 2096.2mg equivalent 2 g cefotaxime (+ 5% overage) - powder for injection - 2 g - active: cefotaxime sodium 2096.2mg equivalent 2 g cefotaxime (+ 5% overage) - cefotaxime is indicated in the treatment of the following infections either before the infecting organism has been identified or when caused by bacteria of established sensitivity. · septicaemia. · respiratory tract infections: acute and chronic bronchitis, bacterial pneumonia, infected bronchiectasis, lung abscess and post-operative chest infections. · urinary tract infections: acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. · soft tissue infections: cellulitis, peritonitis and wound infections. · bone and joint infections: osteomyelitis, septic arthritis. · obstetric and gynaecological infections: pelvic inflammatory disease. · gonorrhoea: particularly if penicillin-resistant. · other bacterial infections: meningitis and other sensitive infections suitable for parenteral antibiotic therapy. the administration of cefotaxime prophylactically may reduce the incidence of certain post-operative infections in patients undergoing surgical procedures that are classified as contaminated or potentially contaminated or in clean operations where infections would have serious effects. protection is best ensured by achieving adequate local tissue concentrations at the time contamination is likely to occur. cefotaxime should therefore be administered immediately prior to surgery and if necessary continued in the immediate post-operative period. administration should usually be stopped within 24 hours since continuing use of any antibiotic in the majority of surgical procedures does not reduce the incidence of subsequent infections.
cefotaxime (aft)
aft pharmaceuticals ltd - cefotaxime sodium 524.05mg equivalent to 500 mg cefotaxime (+ 5% overage) - powder for injection - 500 mg - active: cefotaxime sodium 524.05mg equivalent to 500 mg cefotaxime (+ 5% overage) - cefotaxime is indicated in the treatment of the following infections either before the infecting organism has been identified or when caused by bacteria of established sensitivity. · septicaemia. · respiratory tract infections: acute and chronic bronchitis, bacterial pneumonia, infected bronchiectasis, lung abscess and post-operative chest infections. · urinary tract infections: acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. · soft tissue infections: cellulitis, peritonitis and wound infections. · bone and joint infections: osteomyelitis, septic arthritis. · obstetric and gynaecological infections: pelvic inflammatory disease. · gonorrhoea: particularly if penicillin-resistant. · other bacterial infections: meningitis and other sensitive infections suitable for parenteral antibiotic therapy. the administration of cefotaxime prophylactically may reduce the incidence of certain post-operative infections in patients undergoing surgical procedures that are classified as contaminated or potentially contaminated or in clean operations where infections would have serious effects. protection is best ensured by achieving adequate local tissue concentrations at the time contamination is likely to occur. cefotaxime should therefore be administered immediately prior to surgery and if necessary continued in the immediate post-operative period. administration should usually be stopped within 24 hours since continuing use of any antibiotic in the majority of surgical procedures does not reduce the incidence of subsequent infections.
cefotaxime 1 g powder for solution for injection/infusion
noridem enterprises limited - cefotaxime - powder for solution for injection/infusion - 1 gram(s) - third-generation cephalosporins; cefotaxime
cefotaxime 2 g powder for solution for injection/infusion
noridem enterprises limited - cefotaxime - powder for solution for injection/infusion - 2 gram(s) - third-generation cephalosporins; cefotaxime
cefotaxime 500 mg powder for solution for injection/infusion
noridem enterprises limited - cefotaxime - powder for solution for injection/infusion - 500 milligram(s) - third-generation cephalosporins; cefotaxime